InVivo Therapeutics' CEO to Appear on Fox News Channel's "Tech Take"

InVivo Therapeutics' CEO to Appear on Fox News Channel's "Tech Take"

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to appear live in New York City on Fox News Channel's "Tech Take" on Thursday, June 27th. "Tech Take" is hosted by anchor Adam Housley and airs on Thursdays at 1:00pm ET.

InVivo Therapeutics has pioneered a treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after traumatic SCI. Recently, the U.S. Food and Drug Administration (FDA) granted two approvals to the Company, the first for Humanitarian Use Device (HUD) designation, which the Company believes will expedite the product's path to market, and the second to approve the Company to begin a first-in-man clinical trial of the technology. On the show, Reynolds will discuss the product and the upcoming pilot study, as well as the platform the Company has built for developing new options for a wide range of conditions.

Adam Housley joined Fox News Channel in 2001 as a Los Angeles-based correspondent. Recently, Housley covered the Japanese earthquake and tsunami, reported in both English and Spanish during the Chilean Miners rescue and, earlier in 2010, reported live from Haiti after the deadly earthquake.

Fox News Channel airs locally on channel 841.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit

Safe Harbor Statement

Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the potential up-listing of our common stock to a national securities exchange, and the impact of any such up-listing, such as increasing liquidity an unlocking inherent value in our stock. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to up-list to a national securities exchange, as well as other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2012 and subsequent filings with the SEC.

Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations

KEYWORDS: United States North America Massachusetts


The article InVivo Therapeutics' CEO to Appear on Fox News Channel's "Tech Take" originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.